Leaked: Pfizer SAFETY DATA SHEET

Revision date 19-Mar-2021

1.1. Product identifier Product Name

Product Code(s) Form Synonyms

Trade Name: Compound Number Item Code Chemical Family:

Version 2 Page 1 / 12

Pfizer-BioNTech COVID-19 Vaccine

PF00092
nanoform
Comirnaty; PF-07302048 containing PF-07305885 (BNT162b2); CorVAC Containing PF-07305885 (BNT162b2) ; CoVVAC Containing PF-07305885 (BNT162b2); COVID Vaccine Containing PF-07305885 (BNT162b2); COVID-19 Vaccine Containing PF-07305885 (BNT162b2)
Not applicable
PF-07302048
H000022941: H000023057;H000024547: H000024742
Lipid Nanoparticles containing PF-07305885 (BNT162b2) and Lipids

SAFETY DATA SHEET

Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.2. Relevant identified uses of the substance or mixture and uses advised against Recommended Use Pharmaceutical product
1.3. Details of the supplier of the safety data sheet

Pfizer Inc
235 East 42nd Street
New York, New York 10017 1-800-879-3477

1.4. Emergency telephone number

Emergency Telephone

E-mail address

Pfizer Ireland Pharmaceuticals OSG Building
Ringaskiddy, Co. Cork.
Ireland

+353 21 4378701

Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887 pfizer-MSDS@pfizer.com

Section 2: HAZARDS IDENTIFICATION

2.1. Classification of the substance or mixture

Not classified as hazardous

2.2. Label elements Signal word

Hazard statements

2.3. Other hazards Other hazards

Note:

Not classified
Not classified in accordance with international standards for workplace safety.

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless

PF00092

SAFETY DATA SHEET Product Name Pfizer-BioNTech COVID-19 Vaccine

Revision date 19-Mar-2021

5.2. Special hazards arising from the substance or mixture

Page 4 / 12 Version 2

Specific hazards arising from the chemical

Hazardous combustion products 5.3. Advice for firefighters

Special protective equipment for fire-fighters

Fine particles (such as mists) may fuel fires/explosions. Formation of toxic gases is possible during heating or fire.

Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.

Section 6: ACCIDENTAL RELEASE MEASURES

6.1. Personal precautions, protective equipment and emergency procedures

Personal precautions
For emergency responders
6.2. Environmental precautions Environmental precautions

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.
Use personal protection recommended in Section 8.

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

6.3. Methods and material for containment and cleaning up

Methods for containment Methods for cleaning up

Prevention of secondary hazards 6.4. Reference to other sections Reference to other sections

7.1. Precautions for safe handling

Advice on safe handling

Prevent further leakage or spillage if safe to do so.
Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.
Clean contaminated objects and areas thoroughly observing environmental regulations.

See section 8 for more information. See section 13 for more information.

Section 7: HANDLING AND STORAGE

Restrict access to work area. No open handling permitted. Minimize generating airborne mists and vapors. If solvent based liquid, ground and bond all bulk transfer equipment. Use appropriate engineering controls to maintain exposures below the B-OEB taking all applicable routes of exposure into consideration. A change area to facilitate ‘good laboratory/manufacturing’ decontamination practices is recommended. Avoid inhalation and contact with skin, eye, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

General hygiene considerations Handle in accordance with good industrial hygiene and safety practice.
7.2. Conditions for safe storage, including any incompatibilities
Storage Conditions Store at < -70 °C in properly labeled containers. Keep away from heat, sparks, and flames. 7.3. Specific end use(s)
Specific use(s) Vaccine.

PF00092

SAFETY DATA SHEET Product Name Pfizer-BioNTech COVID-19 Vaccine

Revision date 19-Mar-2021

8.1. Control parameters Exposure Limits

Refer to available public information for specific member state Occupational Exposure Limits.

Page 5 / 12 Version 2

Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

Sucrose

ACGIH TLV Bulgaria Estonia France Ireland

Latvia Spain OSHA PEL

United Kingdom

SODIUM CHLORIDE

Latvia

Russia

Potassium phosphate

Russia

POTASSIUM CHLORIDE

Bulgaria Latvia Russia

Pfizer OEB Statement:

SODIUM CHLORIDE

Pfizer Occupational Exposure

Band (OEB):

ALC-0315

Pfizer Occupational Exposure

Band (OEB):

POTASSIUM CHLORIDE

Pfizer Occupational Exposure

Band (OEB):

PF-07305885

Pfizer Occupational Exposure

Band (OEB):

PF-07302048

Pfizer Occupational Exposure

Band (OEB):

8.2. Exposure controls Engineering controls

10 mg/m3
10.0 mg/m3
10 mg/m3
10 mg/m3
10 mg/m3
STEL: 20 mg/m3 5 mg/m3

10 mg/m3
15 mg/m3
5 mg/m3
(vacated) TWA: 15 mg/m3 total dust (vacated) TWA: 5 mg/m3 respirable fraction TWA: 10 mg/m3

STEL: 20 mg/m3

5 mg/m3
MAC: 5 mg/m3

MAC: 10 mg/m3

5.0 mg/m3
5 mg/m3
MAC: 5 mg/m3

The Biotherapeutic Occupational Exposure Band (B-OEB) is an acceptable daily intake (ADI) range, based on available hazard data with appropriate safety factors applied. Engineering control measures should be utilized to bring exposures into the relevant B-OEB; supplementary administrative controls and personal protective equipment are to be used to achieve exposure control to the bottom of the band.

OEB 1 (control exposure to the range of 1000ug/m3 to 3000ug/m3)

OEB 3 – Contact Hazards Unknown (control exposure to the range of 10ug/m3 to < 100ug/m3)

OEB 1 (control exposure to the range of 1000ug/m3 to 3000ug/m3)
B-OEB Default (control exposure to the range of 10 μg/day to <100 μg/day) B-OEB 5 (control exposure to <10 μg/day)

Engineering controls should be used as the primary means to control exposures. Use process containment, local exhaust ventilation, biosafety cabinet, or other engineering controls to maintain airborne levels within the B-OEB range. It is recommended that all large scale operations should be fully enclosed. Air recirculation is not recommended.

PF00092

SAFETY DATA SHEET
Product Name Pfizer-BioNTech COVID-19 Vaccine Page 6 / 12

Revision date 19-Mar-2021

Environmental exposure controls

Personal protective equipment

Eye/face protection

Hand protection

Skin and body protection

Respiratory protection

General hygiene considerations

Version 2

No information available.

Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes. Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Wear safety glasses as minimum protection (goggles recommended). (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).

Wear impervious disposable gloves (e.g. Nitrile, etc.) as minimum protection (double recommended). (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.).

(Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).

Under normal conditions of use, if the applicable Biotherapeutic Occupational Exposure Band (B-OEB) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the B-OEB (e.g. particulate respirator with a full mask, P3 filter). (Respirators must meet the standards in accordance with EN136, EN143, ASTM F2704-10 or international equivalent.).

Handle in accordance with good industrial hygiene and safety practice.

9.1. Information on basic physical and chemical properties Physical state
Color
Odor

Odor threshold Molecular formula Molecular weight

Property
pH
Melting point / freezing point Boiling point / boiling range Flash point
Evaporation rate Flammability (solid, gas) Flammability Limit in Air

Upper flammability limit:

Lower flammability limit:

Vapor pressure
Vapor density
Relative density
Water solubility Solubility(ies)
Partition coefficient Autoignition temperature

Liquid milky white

Mixture Mixture

Values

7.4

No data available

No data available No data available

protection is recommended (scale dependent). Wear impervious protective clothing when

handling this compound.

PF00092

Wear impervious disposable protective clothing when handling this compound. Full body

Section 9: PHYSICAL AND CHEMICAL PROPERTIES

No information available

If this compound is so risky to the body,

then why on earth would you inject it into the body ???

No data available No data available

SAFETY DATA SHEET Product Name Pfizer-BioNTech COVID-19 Vaccine

Revision date 19-Mar-2021

Decomposition temperature Kinematic viscosity Dynamic viscosity
Particle characteristics

Particle Size

Particle Size Distribution Explosive properties

9.2. Other information

No information available

9.2.1. Information with regard to physical hazard classes

Page 7 / 12 Version 2

No information available

9.2.2. Other safety characteristics

No information available

10.1. Reactivity Reactivity
10.2. Chemical stability Stability
Explosion data

Sensitivity to Mechanical Impact Sensitivity to Static Discharge

No data available.

Stable under normal conditions.

Section 10: STABILITY AND REACTIVITY

10.3. Possibility of hazardous reactions

Possibility of hazardous reactions

No information available.

10.4. Conditions to avoid
Conditions to avoid Fine particles (such as mists) may fuel fires/explosions. As a precautionary measure, keep

away from heat sources and electrostatic discharge. Incompatible materials As a precautionary measure, keep away from strong oxidizers.

10.5. Incompatible materials
10.6. Hazardous decomposition products

Hazardous decomposition products No data available.

11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008 General Information:
Known Clinical Effects:

Acute Toxicity: (Species, Route, End Point, Dose) Sucrose
Rat Oral LD 50 29,700 mg/kg

SODIUM CHLORIDE

Rat Sub-tenon injection (eye) LC50/1hr > 42 g/m3 Rat Oral LD 50 3 g/kg

Toxicological properties have not been thoroughly investigated. The following information is

available for the individual ingredients.

Based on clinical trials in humans, possible adverse effects following intravenous exposure

to this compound may include: injection site pain, muscle pain, headache, fever, chills,

tiredness, joint pain, abnormal redness of skin (erythema), and sleep disturbances. Serious

allergic reactions, including anaphylaxis, have been reported.

PF00092

No data available No data available No data available

SAFETY DATA SHEET Product Name Pfizer-BioNTech COVID-19 Vaccine

Revision date 19-Mar-2021

Mouse Oral LD 50 4 g/kg Rabbit Dermal LD 50 > 10 g/kg POTASSIUM CHLORIDE
Rat Oral LD50 2600 mg/kg Potassium phosphate

Rat Oral LD50 3200 mg/kg
Rabbit Dermal LC50 > 4640 mg/kg

Page 8 / 12 Version 2

Irritation / Sensitization: (Study Type, Species, Severity) SODIUM CHLORIDE
Skin irritation Rabbit Mild
Eye irritation Rabbit Mild

POTASSIUM CHLORIDE

Eye Irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)
PF-07302048
4 Week(s) Rat Intramuscular * 10 μg LOAEL Skin, Blood forming organs, Blood, Skeletal muscle, Lymphoid tissue, Spleen Repeated Dose Toxicity Comments: PF-07302048: * Doses were administered once a week.

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))
PF-07305885
Fertility & Embryonic Development – Females Rat Intramuscular 30 μg NOAEL No effects at maximum dose, Not teratogenic
Potassium phosphate
Reproductive & Fertility Rat No route specified 282 mg/kg/day NOAEL No evidence of impaired fertility or harm to the fetus Reproductive & Fertility Mouse No route specified 320 mg/kg/day NOAEL No evidence of impaired fertility or harm to the fetus

Genetic Toxicity: (Study Type, Cell Type/Organism, Result) Potassium phosphate

Bacterial Mutagenicity (Ames)

Carcinogenicity Cholesterol

IARC

Salmonella Negative See below

Group 3 (Not Classifiable)

Data for the Drug Product
Reproduction & Development Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Fertility & Embryonic Rat Intramuscular N/A Development – Females

11.2. Informationonotherhazards

Not specified

No effects at maximum dose

PF00092

SAFETY DATA SHEET Product Name Pfizer-BioNTech COVID-19 Vaccine

Revision date 19-Mar-2021

11.2.1. Endocrine disrupting properties

Page 9 / 12 Version 2

Endocrine disrupting properties

11.2.2. Otherinformation Other adverse effects

Environmental Overview:

12.1. Toxicity

No information available.

No information available.

Section 12: ECOLOGICAL INFORMATION

Environmental properties have not been investigated. Releases to the environment should be avoided.

Aquatic Toxicity: (Species, Method, End Point, Duration, Result) POTASSIUM CHLORIDE

Gambusia affinis (Mosquitofish) LC50 96 hours 920 mg/L
Lepomis macrochirus (Bluegill Sunfish) LC50 96 hours 2010 mg/L Daphnia Magna (Water Flea) EC50 48 hours 825 mg/L Scenedesmus subspicatus (Green Alga) EC50 72 hours 2500 mg/L

12.2. Persistence and degradability Persistence and degradability

12.3. Bioaccumulative potential Bioaccumulation

12.4. Mobility in soil Mobility in soil

No information available.

No information available.

No information available.

12.5. Results of PBT and vPvB assessment PBT and vPvB assessment .

12.6. Endocrinedisruptingproperties
Endocrine disrupting properties No information available.

12.7. Other adverse effects

No information available.

PF00092

SAFETY DATA SHEET
Product Name Pfizer-BioNTech COVID-19 Vaccine Page 10 / 12

Revision date 19-Mar-2021

13.1. Waste treatment methods

Version 2

Section 13: DISPOSAL CONSIDERATIONS

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Section 14: TRANSPORT INFORMATION

Section 15: REGULATORY INFORMATION

Water

CERCLA/SARA Section 313 de minimus % California Proposition 65
TSCA
EINECS

AICS

Sucrose

CERCLA/SARA Section 313 de minimus % California Proposition 65
TSCA
EINECS

AICS

SODIUM CHLORIDE

CERCLA/SARA Section 313 de minimus % California Proposition 65
TSCA
EINECS

AICS

ALC-0315

CERCLA/SARA Section 313 de minimus % California Proposition 65
EINECS

Potassium phosphate

CERCLA/SARA Section 313 de minimus % California Proposition 65
TSCA
EINECS

AICS

POTASSIUM CHLORIDE

CERCLA/SARA Section 313 de minimus % California Proposition 65
TSCA

Not Listed Not Listed Present 231-791-2 Present

Not Listed Not Listed Present 200-334-9 Present

Not Listed Not Listed Present 231-598-3 Present

Not Listed Not Listed Not Listed

Not Listed Not Listed Present 231-913-4 Present

Not Listed Not Listed Present

PF00092

SAFETY DATA SHEET Product Name Pfizer-BioNTech COVID-19 Vaccine

Page 11 / 12 Version 2

Revision date 19-Mar-2021

EINECS
AICS
Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)

PF-07305885

CERCLA/SARA Section 313 de minimus % California Proposition 65
EINECS

PF-07302048

CERCLA/SARA Section 313 de minimus % California Proposition 65
EINECS

PEGA / ALC-0159

CERCLA/SARA Section 313 de minimus % California Proposition 65
EINECS

Disodium phosphate dihydrate

CERCLA/SARA Section 313 de minimus % California Proposition 65
EINECS
AICS

Standard for Uniform Scheduling of Medicines and

Poisons (SUSMP)

Cholesterol

CERCLA/SARA Section 313 de minimus % California Proposition 65
TSCA
EINECS

AICS
Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)

1,2-Distearoyl-sn-glycero-3-phosphocholine

CERCLA/SARA Section 313 de minimus % California Proposition 65
EINECS

France
Occupational Illnesses (R-463-3, France)

European Union

231-211-8 Present Schedule 4

Not Listed Not Listed Not Listed

Not Listed Not Listed Not Listed

Not Listed Not Listed Not Listed

Not Listed Not Listed Not Listed Present Schedule 5

Not Listed Not Listed Present 200-353-2 Present Schedule 4

Not Listed Not Listed 212-440-2

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work

Authorizations and/or restrictions on use:

This product does not contain substances subject to authorization (Regulation (EC) No. 1907/2006 (REACH), Annex XIV) This product does not contain substances subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

Persistent Organic Pollutants

Not applicable

Ozone-depleting substances (ODS) regulation (EC) 1005/2009

Not applicable

PF00092

SAFETY DATA SHEET Product Name Pfizer-BioNTech COVID-19 Vaccine

Revision date 19-Mar-2021

Plant protection products directive (91/414/EEC)

Page 12 / 12 Version 2

Legend:
TSCA – United States Toxic Substances Control Act Section 8(b) Inventory
EINECS/ELINCS -EuropeanInventoryofExistingChemicalSubstances/EuropeanListofNotifiedChemicalSubstances AICS – Australian Inventory of Chemical Substances

15.2. Chemical safety assessment

Chemical Safety Report No information available

Key or legend to abbreviations and acronyms used in the safety data sheet

Section 16: OTHER INFORMATION

Data Sources: Reason for revision

Revision date Prepared By

Pfizer proprietary drug development information. Publicly available toxicity information.

Updated Section 1 – Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 3 – Composition / Information on Ingredients. Updated Section 11 – Toxicology Information. Updated Section 15 – Regulatory Information.

19-Mar-2021
Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good

faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there

is no known information at this time.

Information is accurate ??? What information ???

When the bulk of the information and data is listed as not available, and is not even provided; then no wonder there is no

warranty for this vaccine.

Who is ready to be a Guinea Pig ???

After all, it is only your health and life at stake.

For the thousands already killed by the COVID vaccine, and for the hundreds of thousands already seriously injured from

the COVID jab; we can safely presume that none of them were shown this so-called Safety Data Sheet.